We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+4.25%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.01B
AUM Growth
+$52.2M
Cap. Flow
+$30.7M
Cap. Flow %
3.04%
Top 10 Hldgs %
32.72%
Holding
140
New
6
Increased
28
Reduced
47
Closed
15

Top Buys

Rank Stock Value
1
TDOC icon
Teladoc Health
TDOC
+$17.7M
2
HUM icon
Humana
HUM
+$13.6M
3
KTWO
K2M Group Holdings, Inc
KTWO
+$13.2M
4
FIT
Fitbit, Inc. Class A common stock
FIT
+$12.2M
5
ESPR
Esperion Therapeutics
ESPR
+$12.1M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$20.4M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$11.6M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$11.4M
4
THC icon
Tenet Healthcare
THC
+$9.34M
5
ONC
BeOne Medicines Ltd
ONC
+$8.53M

Sector Composition

Rank Sector Weight
1 Healthcare 95.24%
2 Industrials 0.39%
3 Financials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONC
51
BeOne Medicines Ltd
ONC
$32.4B
$6.83M 0.68%
40,650
-63,000
-61% -$8.53M
GNMK
52
DELISTED
GenMark Diagnostics, Inc
GNMK
$6.46M 0.64%
1,186,502
+412,825
+53% +$2.05M
COO icon
53
Cooper Companies
COO
$13.9B
$5.1M 0.51%
89,200
– –
TMO icon
54
Thermo Fisher Scientific
TMO
$197B
$4.92M 0.49%
23,848
-1,960
-8% -$411K
NBIX icon
55
Neurocrine Biosciences
NBIX
$17.4B
$4.45M 0.44%
53,650
-850
-2% -$71.8K
NKTR icon
56
Nektar Therapeutics
NKTR
$2.23B
$3.77M 0.37%
2,367
-2,613
-52% -$3.37M
CERN
57
DELISTED
Cerner Corp
CERN
$3.71M 0.37%
64,000
+20,000
+45% +$1.3M
BMRN icon
58
BioMarin Pharmaceuticals
BMRN
$11.5B
$3.6M 0.36%
44,350
-700
-2% -$60.1K
TFX icon
59
Teleflex
TFX
$5.92B
$3.57M 0.35%
14,000
– –
MOH icon
60
Molina Healthcare
MOH
$11.8B
$3.53M 0.35%
43,500
– –
ESRX
61
DELISTED
Express Scripts Holding Company
ESRX
$3.42M 0.34%
49,500
– –
AGIO icon
62
Agios Pharmaceuticals
AGIO
$2.39B
$3.3M 0.33%
40,300
-600
-1% -$46.4K
ALKS icon
63
Alkermes
ALKS
$8.76B
$2.95M 0.29%
50,900
-800
-2% -$46.8K
HSIC icon
64
Henry Schein
HSIC
$9.85B
$2.89M 0.29%
54,825
– –
LGND icon
65
Ligand Pharmaceuticals
LGND
$6.08B
$2.75M 0.27%
26,690
-14,026
-34% -$1.39M
PRGO icon
66
Perrigo
PRGO
$1.45B
$2.75M 0.27%
33,000
– –
XRAY icon
67
Dentsply Sirona
XRAY
$2.78B
$2.74M 0.27%
54,500
– –
ALNY icon
68
Alnylam Pharmaceuticals
ALNY
$36B
$2.59M 0.26%
21,750
-350
-2% -$45.1K
JNJ icon
69
Johnson & Johnson
JNJ
$607B
$2.56M 0.25%
20,000
-6,000
-23% -$811K
SGEN
70
DELISTED
Seagen Inc. Common Stock
SGEN
$2.56M 0.25%
48,850
-4,650
-9% -$253K
BMY icon
71
Bristol-Myers Squibb
BMY
$125B
$2.53M 0.25%
+40,000
New +$2.57M
GMED icon
72
Globus Medical
GMED
$10.3B
$2.43M 0.24%
48,850
– –
BLUE
73
DELISTED
bluebird bio
BLUE
$2.27M 0.23%
1,027
-448
-30% -$1.14M
TRHC
74
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
$2.25M 0.22%
58,000
– –
AGN
75
DELISTED
Allergan plc
AGN
$2.19M 0.22%
13,000
-3,500
-21% -$587K
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2018 Portfolio in Review

As of Q1 2018, Bellevue Group held 140 positions worth $1.01B, up 5.4% from $957M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group deployed $30.7M of net new capital in Q1 2018, opening 6 new positions and adding to 28 existing holdings. Its largest new stake was K2M Group Holdings, Inc: 667,941 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $11.4M trimmed.

  • Bellevue Group's largest Q1 2018 buy was K2M Group Holdings, Inc: 667,941 shares worth $12.7M.
  • Bellevue Group added most to Teladoc Health in Q1 2018, an estimated $17.7M increase.
  • Bellevue Group's biggest Q1 2018 reduction was Teva Pharmaceuticals, cutting an estimated $11.4M.
  • Bellevue Group fully exited Eli Lilly in Q1 2018, selling an estimated $20.4M.
  • Bellevue Group's ten largest holdings make up 33% of its $1.01B portfolio in Q1 2018.
  • Bellevue Group opened 6 new positions and closed 15 in Q1 2018.
  • Bellevue Group's portfolio value rose 5.4% quarter-over-quarter to $1.01B.

Based on Bellevue Group's 13F filing for Q1 2018, filed 9 May 2018.